newsfilter
← Earnings
Earnings Releases·

Xenon Pharmaceuticals — Q3 2026 Earnings Summary

  • Reported a net loss of $110.4 million for Q3 2026, widening from $90.9 million in the prior year period, while cash and marketable securities increased to $1,153.5 million as of September 30, 2026.
  • Submitted the New Drug Application (NDA) for azetukalner in focal seizures in September 2026 and anticipates topline data from the Phase 3 X-NOVA2 MDD study in December 2026.
  • Plans to initiate the Phase 3b/4 X-FIRST study for azetukalner in Q1 2027 and Phase 2 proof-of-concept studies for pain programs XEN1701 and XEN1120 in H1 2027.
  • Anticipates cash runway sufficient to fund operations into 2029 based on current operating plans, despite a net loss of $323.5 million for the nine months ended September 30, 2026.
Company
XENON PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology